Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bosutinib - Pfizer

Drug Profile

Bosutinib - Pfizer

Alternative Names: Bosulif; Bosutinib monohydrate - Pfizer; PF-05208763; PF-5208763; SKI-606

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Aniline compounds; Antineoplastics; Chlorine compounds; Nitriles; Piperazines; Quinolines; Small molecules; Urologics
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Glioblastoma
  • Phase I/II Amyotrophic lateral sclerosis; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Autosomal dominant polycystic kidney disease; Breast cancer; Solid tumours

Most Recent Events

  • 25 Mar 2024 Launched for Chronic myeloid leukaemia (First-line therapy) in South Korea (PO) (NCT06297161)
  • 25 Mar 2024 Launched for Chronic myeloid leukaemia (Second-line therapy or greater) in South Korea (PO) (NCT06297161)
  • 03 Oct 2023 Chemical structure information added for the salt form of the drug
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top